| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 1,529 | 1,430 | 1,439 | 1,327 | 1,466 | 1,405 | 1,365 | 1,444 | 1,576 | 1,545 | 1,628 | 2,045 | 2,247 | 2,056 | 2,249 | 2,382 | 2,346 | 2,163 | 2,249 | 1,544 | 1,563 | 1,175 | 1,631 | 1,838 | 1,614 | 1,617 | 1,638 | 1,304 | 1,513 | 1,452 | 1,598 | 1,543 | 1,682 | 1,575 | 1,686 | 1,714 | 1,764 | 2,130 | 1,764 | 1,823 | 1,928 | 1,891 | 1,968 | 2,137 | 2,296 |
| Expenses | 1,323 | 1,121 | 1,129 | 1,061 | 1,192 | 1,051 | 1,045 | 1,126 | 1,293 | 1,219 | 1,336 | 1,651 | 1,794 | 1,663 | 1,828 | 1,899 | 2,262 | 1,747 | 1,798 | 1,141 | 1,131 | 977 | 1,242 | 1,293 | 1,216 | 1,269 | 1,319 | 1,116 | 1,280 | 1,259 | 1,440 | 1,408 | 1,459 | 1,419 | 1,439 | 1,459 | 1,656 | 1,480 | 1,477 | 1,554 | 1,587 | 1,611 | 1,631 | 1,873 | 1,964 |
| EBITDA | 206 | 309 | 310 | 266 | 274 | 354 | 319 | 318 | 283 | 327 | 293 | 394 | 453 | 393 | 422 | 483 | 83 | 415 | 451 | 403 | 432 | 199 | 389 | 546 | 398 | 348 | 319 | 187 | 233 | 192 | 158 | 134 | 223 | 156 | 247 | 255 | 108 | 650 | 287 | 269 | 341 | 280 | 337 | 264 | 332 |
| Operating Profit % | 13 % | 21 % | 21 % | 20 % | 19 % | 25 % | 23 % | 22 % | 17 % | 21 % | 18 % | 19 % | 19 % | 19 % | 19 % | 19 % | 4 % | 19 % | 20 % | 24 % | 24 % | 13 % | 20 % | 26 % | 22 % | 21 % | 19 % | 14 % | 15 % | 13 % | 9 % | 8 % | 12 % | 9 % | 14 % | 12 % | 5 % | 14 % | 15 % | 14 % | 17 % | 14 % | 17 % | 12 % | 14 % |
| Depreciation | 66 | 70 | 75 | 75 | 127 | 72 | 72 | 73 | 75 | 73 | 79 | 82 | 182 | 88 | 90 | 98 | 95 | 103 | 117 | 84 | 98 | 82 | 85 | 96 | 86 | 88 | 100 | 93 | 101 | 95 | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 |
| Interest | 85 | 91 | 92 | 89 | 99 | 83 | 80 | 98 | 80 | 69 | 66 | 77 | 73 | 51 | 54 | 53 | 62 | 73 | 72 | 49 | 47 | 48 | 47 | 46 | 43 | 35 | 35 | 37 | 40 | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 57 |
| Profit Before Tax | 68 | 168 | 161 | 145 | 69 | 218 | 193 | 166 | 160 | 203 | 168 | 261 | 227 | 286 | 302 | 356 | -40 | 269 | 292 | 294 | 358 | 106 | 299 | 431 | 297 | 247 | 208 | 70 | 106 | 69 | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 131 | 206 | 154 | 190 | 93 | 176 |
| Tax | 25 | 37 | 36 | 24 | 58 | 54 | 50 | 48 | 11 | 60 | 43 | 48 | 74 | 86 | 92 | 88 | 61 | 84 | 43 | 90 | 98 | 18 | 75 | 121 | 83 | 86 | 65 | 19 | 47 | 22 | 32 | 25 | 14 | 19 | 36 | 35 | 8 | 18 | 42 | 30 | 55 | 52 | 70 | 38 | 57 |
| Net Profit | 43 | 130 | 125 | 122 | 11 | 164 | 144 | 118 | 149 | 144 | 126 | 213 | 152 | 200 | 210 | 268 | -101 | 185 | 249 | 203 | 261 | 88 | 224 | 310 | 214 | 161 | 143 | 51 | 59 | 47 | 5 | -16 | -101 | 6 | 62 | 66 | -62 | 482 | 103 | 101 | 151 | 103 | 120 | 56 | 119 |
| EPS in ₹ | 2.68 | 8.28 | 8.11 | 7.90 | 0.72 | 10.39 | 9.29 | 7.66 | 9.63 | 9.44 | 8.23 | 13.64 | 9.94 | 13.00 | 13.50 | 16.74 | -6.38 | 11.61 | 15.66 | 12.77 | 16.35 | 5.53 | 14.06 | 19.46 | 13.43 | 10.09 | 8.97 | 3.20 | 3.74 | 2.96 | 0.34 | -0.98 | -6.15 | 0.40 | 3.94 | 4.22 | -3.69 | 30.44 | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 |
Jubilant Pharmova
Jubilant Pharmova
961.65
-15.75
(-1.61%)
Market Cap
15,317.27 Cr
PE Ratio
39.19
Volume
70,552.00
Day High - Low
979.95 - 956.25
52W High-Low
1,248.00 - 786.05
There are 2 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
15,317.27 Cr
EPS
25.15
PE Ratio
39.19
PB Ratio
2.20
Book Value
445.26
EBITDA
1,145.70
Dividend Yield
0.51 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
13.41
Debt to Equity
0.55
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
Jubilant Pharmova schedules 48th AGM for Aug 26, 2026. Board recommends ₹5 dividend per share. Record date is July 24, 2026. Shareholders must submit TDS docs by Aug 14.
Jubilant Pharmova seeks MD re-approvals
Jul 18, 2026
Jul 18, 2026Jubilant Pharmova seeks shareholder approval via postal ballot to re-appoint Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia as Managing Directors for three years from June 1, 2026.
Jubilant Pharmova received a rectification order deleting a tax demand of Rs 22.10 crores for AY 2020-21. The order was received on July 15, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,001.10 | #1 4,80,130.92 | 41.48 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 70.23 | |
7,835.00 | 2,07,994.63 | 80.57 | 11,067.00 | 13.95 | 2,568 | 13.44 | 78.93 | |
4,872.10 | 1,85,319.02 | 86.77 | 13,886.20 | 20.34 | 2,138 | -26.91 | 52.19 | |
1,466.40 | 1,18,462.44 | 35.47 | 29,044.60 | 2.24 | 3,870 | -39.18 | 60.03 | |
1,115.10 | 1,12,205.15 | 21.85 | 27,657.90 | 17.64 | 5,026 | 7.82 | 49.15 | |
2,421.20 | 1,10,705.14 | #1 20.92 | 29,038.90 | #1 26.75 | 5,356 | 87.72 | 50.28 | |
2,575.90 | 1,06,383.63 | 55.24 | 14,636.40 | 14.85 | 1,938 | 31.75 | 56.18 | |
1,781.30 | 96,164.65 | 88.29 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.83 | |
1,144.80 | 95,552.92 | 29.97 | 35,058.60 | 3.90 | 4,158 | -69.10 | 27.15 | |
1,576.30 | 90,696.82 | 26.38 | 33,384.70 | 3.21 | 3,376 | 1.99 | 56.67 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.81 %
Net Income Growth
-45.79 %
Cash Flow Change
10.38 %
ROE
900.75 %
ROCE
151.75 %
EBITDA Margin (Avg.)
-18.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 8,619 | 8,824 | 9,041 | 9,618 | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 11,549 | 12,756 | 15,523 |
| Fixed Assets | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 8,180 |
| Current Assets | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,509 | 3,762 | 3,876 | 3,577 | 4,109 |
| Capital Work in Progress | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 2,962 |
| Investments | 0 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 1,232 |
| Other Assets | 3,111 | 3,023 | 3,147 | 3,423 | 4,804 | 5,344 | 3,171 | 3,792 | 4,156 | 4,312 | 3,907 | 0 |
| Total Equity & Liabilities | 8,619 | 8,824 | 9,041 | 9,618 | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 11,549 | 12,756 | 15,523 |
| Current Liabilities | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,592 | 1,772 | 1,889 | 2,165 | 2,539 |
| Non Current Liabilities | 4,036 | 3,432 | 3,968 | 3,578 | 4,570 | 4,299 | 3,128 | 3,083 | 3,993 | 4,238 | 4,353 | 5,888 |
| Total Equity | 2,454 | 2,928 | 3,389 | 4,035 | 4,809 | 5,604 | 4,742 | 5,316 | 5,392 | 5,421 | 6,239 | 7,093 |
| Reserve & Surplus | 2,438 | 2,951 | 3,421 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 7,077 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -82 | -52 | 117 | -212 | 761 | 225 | -652 | 482 | 30 | -58 | 132 |
| Investing Activities | -362 | -309 | -465 | -614 | -1,018 | -267 | -727 | -323 | -474 | -596 | 513 |
| Operating Activities | 783 | 1,099 | 1,269 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | 971 | 1,072 |
| Financing Activities | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | -433 | -1,453 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 47.68 % | 47.68 % | 47.68 % | 47.68 % | 47.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 23.21 % | 0.00 % | 19.06 % | 19.49 % | 17.94 % | 16.96 % | 17.22 % | 17.40 % | 16.57 % | 15.96 % | 15.90 % | 15.87 % |
| DIIs | 0.78 % | 1.15 % | 0.40 % | 0.43 % | 0.05 % | 0.04 % | 0.39 % | 1.62 % | 0.40 % | 1.63 % | 1.65 % | 1.50 % | 3.78 % | 4.07 % | 5.66 % | 6.98 % | 7.05 % | 9.53 % | 10.52 % | 11.22 % | 11.62 % | 12.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.24 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.07 % | 16.98 % | 19.03 % | 18.97 % | 19.27 % | 19.35 % | 19.01 % | 18.68 % | 18.69 % | 18.25 % | 18.24 % | 18.76 % | 18.71 % | 17.79 % | 18.09 % | 18.09 % | 17.75 % | 17.97 % | 18.02 % | 17.85 % | 17.57 % | 17.16 % |
| Others | 32.47 % | 31.19 % | 29.89 % | 29.92 % | 30.00 % | 29.93 % | 29.92 % | 29.02 % | 28.98 % | 29.44 % | 6.22 % | 29.06 % | 7.77 % | 7.97 % | 7.63 % | 7.30 % | 7.31 % | 7.42 % | 7.22 % | 7.29 % | 7.23 % | 6.89 % |
| No of Share Holders | 0 | 61,942 | 87,493 | 1,13,776 | 1,09,420 | 1,08,063 | 1,09,410 | 1,05,632 | 97,935 | 93,375 | 89,376 | 86,588 | 92,264 | 81,992 | 89,456 | 1,02,442 | 96,526 | 99,673 | 93,336 | 90,133 | 86,347 | 82,703 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3 | 3 | 4.5 | 5 | 5 | 5 | 5 | 5 | 5 | 0.00 |
| Dividend Yield (%) | 0.36 | 0.45 | 1.81 | 0.73 | 1.29 | 1.79 | 0.88 | 0.56 | 0.61 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Feb 2021 |  Change Of Name | NA | 01 Feb 2021 | 886.60 | 886.60 |
| 06 Aug 2021 |  Dividend | ₹ 5.00 /share | 05 Aug 2021 | 843.05 | 657.45 |
| 12 Aug 2022 | Dividend | ₹ 5.00 /share | 11 Aug 2022 | 397.10 | 353.35 |
| 10 Aug 2023 | Dividend | ₹ 5.00 /share | 10 Aug 2023 | 362.90 | 404.75 |
| 02 Aug 2024 | Dividend | ₹ 5.00 /share | 02 Aug 2024 | 703.90 | 866.20 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 849.00 | 920.60 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 1,228.25 | 1,108.05 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 937.70 | 954.95 |
| 16 May 2025 | Quarterly Result Announcement | NA | 16 May 2025 | 896.35 | 905.60 |
| 25 Jul 2025 | Dividend | ₹ 5.00 /share | 25 Jul 2025 | 905.60 | 1,175.00 |
| 29 Jul 2025 | Quarterly Result Announcement | NA | 29 Jul 2025 | 1,210.30 | 1,174.20 |
| 29 Aug 2025 | Annual General Meeting | NA | 29 Aug 2025 | 1,119.10 | 1,039.30 |
| 31 Oct 2025 | Quarterly Result Announcement | NA | 31 Oct 2025 | 1,097.50 | 1,118.40 |
| 06 Feb 2026 | Quarterly Result Announcement | NA | 06 Feb 2026 | 946.80 | 974.50 |
| 22 May 2026 | Quarterly Result Announcement | NA | 22 May 2026 | 946.30 | 1,011.65 |
| 24 Jul 2026 | Dividend | ₹ 5.00 /share | 24 Jul 2026 | 1,011.65 | 970.85 |
Announcements
Submission Of Copies Of Newspaper Advertisement Relating To Notice To Shareholders - Transfer Of Equity Shares/Dividend To IEPF5 hrs ago
5 hrs agoBoard Meeting Intimation for Intimation Of Board Meeting Scheduled For August 07 20266 hrs ago
6 hrs agoAnnouncement Under Regulation 30 (LODR) - Communication Sent To Shareholders Relating To Notice Of Transfer To IEPF1 day ago
1 day agoSubmission Of Copies Of Newspaper Publications - Annual General Meeting Of Jubilant Pharmova Limited Scheduled To Be Held On Wednesday August 26 2026 Through Video Conferencing/Other Audio Visual Means.
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2026
Jul 19, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotJul 18, 2026
Jul 18, 2026Rectification Order From The Income Tax DepartmentJul 16, 2026
Jul 16, 2026Approval For Grant Of Stock Options/Rsus/PsusJul 16, 2026
Jul 16, 2026Disclosure under Regulation 30A of LODRJul 16, 2026
Jul 16, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 02, 2026
Jul 02, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2026
Jul 01, 2026Receipt Of Rectification OrderJun 30, 2026
Jun 30, 2026Closure of Trading WindowJun 29, 2026
Jun 29, 2026Tentative Approval For Panto-Prazole Sodium DRJun 26, 2026
Jun 26, 2026Rectification Order Received From Tax Department In The Matter Of Jubilant Generics LtdJun 24, 2026
Jun 24, 2026Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 19, 2026
Jun 19, 2026Completion Of USFDA InspectionJun 19, 2026
Jun 19, 2026USFDA Inspection Update - Contract Manufacturing Facility At Montreal CanadaMay 29, 2026
May 29, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
May 27, 2026Earnings Call TranscriptMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2026
May 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2026
May 22, 2026Tax Demand Order Received By Companys Step Down SubsidiaryMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 22, 2026
May 22, 2026Record DateMay 22, 2026
May 22, 2026Corporate Action-Board approves DividendMay 22, 2026
May 22, 2026Audited Financial Results For The Quarter And Year Ended March 31. 2026May 22, 2026
May 22, 2026Board Meeting Outcome for Outcome Of Meeting Held On May 22 2026May 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 21, 2026
May 21, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 18, 2026
May 18, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 29, 2026
Apr 29, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 24, 2026
Apr 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 24, 2026
Apr 24, 2026Board Meeting Intimation for Meeting Held On May 22 2026Apr 24, 2026
Apr 24, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 01, 2026
Apr 01, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 31, 2026
Mar 31, 2026Submission Of Communication Sent To ShareholdersMar 30, 2026
Mar 30, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 27, 2026
Feb 27, 2026USFDA Communication Montreal CanadaFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2026
Feb 07, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Feb 06, 2026Un-Audited Financial Results For Quarter And Nine Months Ended December 31 2025Feb 06, 2026
Feb 06, 2026Board Meeting Outcome for Meeting Held On February 06 2026Feb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Feb 02, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Feb 02, 2026Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025Jan 22, 2026
Jan 22, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 48.46
ATR(14)
Less Volatile 26.49
STOCH(9,6)
Neutral 25.09
STOCH RSI(14)
Oversold 14.46
MACD(12,26)
Bearish -3.56
ADX(14)
Weak Trend 14.83
UO(9)
Bearish 43.83
ROC(12)
Uptrend And Accelerating 0.48
WillR(14)
Neutral -70.68
About Jubilant Pharmova
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more
Website
Chairperson NameShyam S Bhartia
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
